Batu Seeks New Approach to Inhibit Immune Checkpoints

Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells

Immune Checkpoint Silenced T Cells for More Potent, Longer Lasting Anti-Tumor Responses

Batu Biologics, an immuno-oncology company, has recently filed intellectual property and initiated discovery research on a new method of augmenting an anti-tumor immune response through ex vivo manipulation of the patient’s T cells.

Read the full article at